FibroGen to Report Third Quarter 2023 Financial Results

Rhea-AI Summary

FibroGen, Inc. to announce third quarter 2023 financial results on November 6 after market close.

Positive

• Investors can gain insights into FibroGen's corporate and financial performance during the conference call.

Negative

• None.

SAN FRANCISCO, Oct. 23, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its third quarter 2023 financial results on Monday, November 6 after the market close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance.

Conference Call and Audio Webcast
Interested parties may access a live audio webcast of the conference call via the “Investor Relations” page of the Company’s website at www.fibrogen.com. To access the call by phone, please go to this link (registration link), and you will be provided with dial-in details. To avoid delays, we encourage participants to dial in to the conference call fifteen minutes ahead of the scheduled start time. A replay of the webcast will also be available for a limited time at the following link (webcast replay).

About FibroGen  
FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing, and commercializing a pipeline of first-in-class therapeutics. The Company applies its pioneering expertise in connective tissue growth factor (CTGF) biology and hypoxia-inducible factor (HIF) to advance innovative medicines for the treatment of unmet needs. Pamrevlumab, an anti-CTGF human monoclonal antibody, is in clinical development for the treatment of locally advanced unresectable pancreatic cancer (LAPC) and metastatic pancreatic cancer. Roxadustat (爱瑞卓^®, EVRENZO™) is currently approved in China, Europe, Japan, and numerous other countries for the treatment of anemia in CKD patients on dialysis and not on dialysis. Roxadustat is in clinical development for chemotherapy-induced anemia (CIA) in China. FibroGen recently expanded its research and development portfolio to include product candidates in the oncology space. For more information, please visit www.fibrogen.com.

Contacts: FibroGen, Inc.

Investors:
David DeLucia, CFA
Vice President, Corporate FP&A / Investor Relations
ddelucia@fibrogen.com

Media:
Meichiel Jennifer Keenan
Investor Relations and Corporate Communications
mkeenan@fibrogen.com

FAQ

When will FibroGen announce its third quarter 2023 financial results?

FibroGen will announce its third quarter 2023 financial results on November 6 after the market close.

What time is the conference call scheduled for?

The conference call is scheduled for 5:00 PM Eastern Time.

Where can interested parties access the live audio webcast of the conference call?

Interested parties can access the live audio webcast on the "Investor Relations" page of FibroGen's website at www.fibrogen.com.

Will there be a replay of the webcast available?

Yes, a replay of the webcast will be available for a limited time at the provided link.